Article info

Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events

Authors

  1. Correspondence to Dr Ildiko Lingvay; Ildiko.Lingvay{at}UTSouthwestern.edu
View Full Text

Citation

Lingvay I, Hansen T, Macura S, et al
Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events

Publication history

  • Received June 19, 2020
  • Revised September 8, 2020
  • Accepted September 8, 2020
  • First published October 28, 2020.
Online issue publication 
October 28, 2020
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.